Ocumension Therapeutics' (HKG:1477) loss narrowed to 268.3 million yuan in 2024 from 379.8 million yuan in 2023.
Loss per share at the drug manufacturer narrowed to 0.39 yuan from 0.59 yuan in the previous year, according to a Monday filing with the Hong Kong bourse.
Revenue grew 69% to 417.3 million yuan from 246.4 million yuan a year earlier.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.